Oncogene protein co-expression: Value of Ha-ras, c-myc, c-fos, and p53 as prognostic discriminants for breast carcinoma

Annals of Surgery

Volumn 221, Issue 6, 1995, Pages 706-720

  Bland, Kirby I ^a,b   Konstadoulakis, Manos M ^a   Vezeridis, Michael P ^a   Wanebo, Harold J ^a  

^a BROWN UNIVERSITY   (United States)

^b RHODE ISLAND HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOPROTEIN; PROTEIN P53;

ARTICLE; BREAST CARCINOMA; CANCER INVASION; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; FOLLOW UP; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MASTECTOMY; ONCOGENE C FOS; ONCOGENE C MYC; ONCOGENE H RAS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION;

BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, RAS; HUMAN; NEOPLASM RECURRENCE, LOCAL; ONCOGENE PROTEINS; PROGNOSIS; PROTEIN P53; PROTO-ONCOGENE PROTEINS C-FOS; PROTO-ONCOGENE PROTEINS C-MYC; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 0029054770     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000658-199506000-00010     Document Type: Article

References (75)

1. Feuer EJ, Wun LM, Boring CC, et al. The lifetime risk of developing breast cancer. J Natl Cancer Inst 1993; 85:892-897.
2. Clark GM, McGuire WL, Hubay CA, et al. Progesterone receptor as a prognostic factor in stage II breast cancer. N Engl J Med 1983; 309:1343-1347.
3. Tandon AK, Clark GM, Chamness GC, et al. HER-2/neu oncogens protein and prognosis in breast cancer. J Clin Oncol 1989; 7: 1120-1128.
4. Rosen PP, Groshen S, Saigo PE, et al. Pathological prognostic factors in stage I (TNM) and stage II (TNM) breast carcinoma: a study of 6744 patients with median follow-up of 18 years. J Clin Oncol 1993; 7:1239.
5. Fisher B, Redmond C, Fisher ER, et al. Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node-negative breast and bowel project protocol B-06. J Clin Oncol 1988; 6:1076.
6. Gilchrist K, Gray R, Fowble B, et al. Tumor necrosis is a histoprognosticator for early recurrence and death in stage II breast cancer. Lab Invest 1988; 58:34A (abstract).
7. Neville AM, Bettelheim R, Gelber RD, et al. Factors predicting treatment responsiveness and prognosis in node-negative breast cancer. J Clin Oncol 1992; 10:696-705.
8. Dressler LG, Seamer LC, Owens MA, et al. DNA flow cytometry and prognostic factors in 1331 frozen breast cancer specimens. Cancer 1988; 61:420-421.
9. Clark GM, Dressler LG, Owens MA, et al. Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N Engl J Med 1989; 320:627-633.
10. Elledge RM, McGuire WL, Osborne CK. Prognostic factors in breast cancer. Semin Oncol 1992; 19:244-253.
11. Osborne CK. Receptors. In Harris JR, Hellman S, Henderson JC, eds. Breast Disease. Philadelphia: JB Lippincott, 1991, pp 301-325.
12. Silvestrini R, Benini E, Dardone MG, et al. p53 as an independent prognostic marker in lymph node-negative breast cancer patients. J Natl Cancer Inst 1993; 85:965-970.
13. Clark GM, McGuire WL. Steroid receptors and other prognostic factors in primary breast cancer. Semin Oncol 1988; 15:20-25.
14. Mathiesen O, Bonderup O, Carl J., et al. The prognostic value of estrogen and progesterone receptors in female breast cancer: a single center study. Acta Oncol 1991; 30:691-695.
15. Nomura Y, Miura S, Koyama H, et al. Relative effect of steroid hormone receptors on the prognosis of patients with operable breast cancer: a univariate and multivarate analysis of 3089 Japanese patients with breast cancer from the study group for the Japanese Breast Cancer Society on hormone receptors and prognosis in breast cancer. Cancer 1992; 69:153-164.
16. Haves DF. Tumor markers for breast cancer. Ann Oncol 1993; 4: 807-819.
17. Coon JS, Deitch AD, de Vere White RW, et al. Interinstitutional variability in DNA flow cytometric analysis of tumors: the National Cancer Institute's flow cytometry network experience. Cancer 1988; 61:126-130.
18. Kute TE, Muss HB, Cooper MR, et al. The use of flow cytometry for the prognosis of stage II adjuvant treated breast cancer patients. Cancer 1990; 66:1810-1816.
19. Sahin AA, Ro J, Ro JY, et al. Ki-67 immunostaining in node-negative stage I/II breast carcinoma: significant correlation with prognosis. Cancer 1991; 68:549-557.
20. 25 ras oncoproteins in human cancers. Cancer Res 1986; 46:1465-1470.
21. Andres AC, Bchini O, Schubaur B, et al. H-ras induced transformation of mammary epithelium is favoured by increased oncogene expression or by inhibition of mammary regression. Oncogene 1991; 6:771-779.
22. Hayes DF, Mesa-Tejada R, Papsidero L, et al. Prediction of prognosis in primary breast cancer by detection of a high molecular weight mucin-like antigen using monoclonal antibodies DF3, F36/ 22, and CU18: a cancer and leukemia group B study. J Clin Oncol 1991; 9:1-10.
23. Tandon A, Clark G, Chamness G, et al. Cathepsin D and prognosis in breast cancer. N Engl J Med 1990; 322:297-302.
24. Duffy MJ, O'Grady P, Devaney D, et al. Tissue-type plasminogen activator, a new prognostic marker in breast cancer. Cancer Res 1988; 48:1348-1349.
25. Harris JR, Lippman ME, Veronesi U, et al. Breast cancer. N Engl J Med 1992; 327:473-480.
26. Borg A, Tandon AK, Sigurdsson H, et al. HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res 1990; 50:4332-4337.
27. Toikkanen S, Helin H, Isola J, et al. Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up. J Clin Oncol 1992; 10:1044-1048.
28. Caleffi M, Teague MW, Jensen RA, et al. p53 gene mutations and steroid receptor status in breast cancer. Cancer 1994; 73:2147-2156.
29. Lipponen P, Ji H, Saaltomaa S, et al. p53 protein expression in breast cancer as related to histopathological characteristics and prognosis. Int J Cancer 1993; 55:51-56.
30. Iggo R, Gatter K, Bartek J, et al. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 1990; 335: 675-679.
31. Rodrigues NR, Rowan A, Smith MEF, et al. p53 mutations in colorectal cancer. Proc Nat Acad Sci 1990; 87:7555-7559.
32. Sidransky D, Von Eschenbach A, Tsai YC, et al. Identification of p53 gene mutations in bladder cancers and urine samples. Science 1991; 252:706-709.
33. Barton CM, Staddon SL, Hughes CM, et al. Abnormalities of the p53 suppressor gene in human pancreatic cancer. Br J Cancer 1991; 64:1076-1082.
34. Thompson AM, Anderson TJ, Condie A, et al. p53 allele losses, mutations and expression in breast cancer and their relationship to clinico-pathological parameters. Int J Cancer 1992; 50:528-532.
35. Sawan A, Randall B, Angus B, et al. Retinoblastoma and p53 gene expression related to relapse and survival in human breast cancer: an immunohistochemical study. J Pathol 1992; 168:23-28.
36. Thor AD, Moore DH II, Edgerton SM, et al. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancer. J Natl Cancer Inst 1992; 84:845-855.
37. Isola J, Visakorpi T, Holli K, et al. Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst 1992; 84:1109-1114.
38. Allred DC, Clark GM, Elledge R, et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993; 85:200-206.
39. Marks JR, Humphrey PA, Wu K, et al. Overexpression of p53 and HER-2/neu proteins as prognostic markers in early stage breast cancer. Ann Surg 1994; 219:332-341.
40. Ostrowski JL, Sawan A, Henry L, et al. p53 expression in human breast cancer related to survival and prognostic factors: an immunohistochemical study. J Pathol 1991; 164:75-81.
41. Banks I, Matlashewski G, Crawford L. Isolation of human p53 specific monoclonal antibodies and their use in the studies of human p53 expression. Eur J Biochem 1986; 159:529-534.
42. Hsu SM, Raine L, Fanger H. Use of avidin-biotin peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981; 29:45-48.
43. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 54:457-481.
44. Cox DR. Regression models and life tables (with discussion). J Roy Stat Soc 1972; 34 (Series B):187-220.
45. Varmus H. An historical overview of oncogenes. In Weinberg RA, ed. Oncogenes and the Molecular Origins of Cancer. Plainview, NY: Cold Spring Harbor Laboratory Press, 1989, p 67.
46. MacKay SLD, Bennett NT, Bland KI, et al. Growth factors, tumor suppressors, and cancer. Perspect Gen Surg 1992; 3:1-62.
47. Cantley LC, Auger KR, Carpenter C, et al. Oncogenes and signal transduction. Cell 1991; 64:281.
48. Weinberg RA. Oncogenes, tumor supppressor genes and cell transformation: trying to put it all together. In Brugge J, Curran T, Harlow E, McCormick F, eds. Origins of Human Cancer. Plainview, NY: Cold Spring Harbor Laboratory Press, 1991, p 1.
49. Dean M, Vande Woude GF. Principles of molecular cell biology of cancer: introduction to methods in molecular biology. In DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 3rd ed. Philadelphia: JB Lippincott, 1989, p 14.
50. Morrison BW. Oncogenes and breast cancer. In Harris JR, Hellman S, Henderson IC, Kinne DW, eds. Breast Diseases. 2nd ed. Philadelphia: JB Lippincott, 1991, p 197.
51. Morrison BW. The genetics of breast cancer. Hematol Oncol Clin North Am 1994; 8:15-27.
52. Bishop JM. Molecular themes in oncogenesis. Cell 1991; 64:235.
53. Callahan R, Campbell G. Mutations in human breast cancer: an overview. J Natl Cancer Inst 1989; 81:1780-1786.
54. Adnane J, Gaudray P, Simon MP, et al. Proto-oncogene amplification and human breast tumor phenotype. Oncogene 1989; 4: 1389-1395.
55. Kraus MH, Yuasa Y, Aaronson SA. A position 12-activated H-ras oncogene in all HS578T mammary carcinosarcoma cells but not normal mammary cells of the same patient. Proc Natl Acad Sci 1984; 81:5384-5388.
56. 25 ras oncoproteins in human cancers. Cancer Res 1986; 46:1465-1470.
57. Clair T, Miller WR, Cho-Chung YS. Prognostic significance of the expression of a ras protein with a molecular weight of 21,000 by human breast cancer. Cancer Res 1987; 47:5290-5293.
58. Bchini O, Andres AC, Schubaur B, et al. Precocious mammary galnd development and milk protein synthesis in transgenic mice ubiquitously expressing human growth hormone. Endocrinology 1991; 128:539-546.
59. Ernberg IT. Oncogenes and tumor growth factors in breast cancer. Acta Oncologica 1990; 29:331-334.
60. Mooi WJ, Peterse JL. Progress in molecular biology of breast cancer. Eur J Cancer 1992; 28:623-625.
61. Van de Vijver MJ, Peterse JL, Mooi WJ, et al. Oncogene activation in human breast cancer. Cancer Cells 1989; 7:385-391.
62. Parkes HC, Lillycrop K, Howell A, et al. c-erb B-2 mRNA expression in human breast tumors: comparison with c-erb B-2 DNA amplification and correlation prognosis. Br J Cancer 1990; 61:39.
63. Winstanley J, Cooke T, Murray GD, et al. The long-term prognostic significance of c-erb B-2 in primary breast cancer. Br J Cancer 1991; 63:447.
64. Klijin JG, Berns PM, Van Putten WL, et al. The prognostic value of oncogene amplification and of tumoral secretory proteins with respect to response to endocrine and chemotherapy in metastatic breast cancer. J Clin Oncol 1992; 11:53.
65. Berns PM, Foekens JA, Van Staveren L, et al. Amplification of the HER-2/neu gene and not of the c-myc in association with poor response to endocrine and good response to chemotherapy in recurrent breast cancer. Presented at the 5th European Organization for Research of Treatment of Cancer Breast Cancer Working Conference; September 3-6, 1991; Leuven.
66. Gullick W, Love SB, Wright C, et al. c-erb B-2 protein over-expression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer 1991; 63:434.
67. Zeillinger R, Kury F, Czerwenka K, et al. HER-2 amplification, steroid receptors and epidermal growth factor receptor in primary breast cancer. Oncogene 1989; 4:109.
68. Shiu RP, Watson PH, Dubik D. c-myc oncogene expression in estrogen-dependent and independent breast cancer. Clin Chem 1993; 39:353-355.
69. Varely JM, Swallow JF, Brammar WJ, et al. Alterations either to c-erb, B-2(neu) or c-myc proto-oncogene in breast carcinomas correlate with poor short-term prognosis. Oncogene 1987; 1:423-430.
70. Dati C, Muraca R, Tazartes O, et al. c-erbB-2 and ras expression levels in breast cancer are correlated and show a co-operative association with unfavorable clinical outcome. Int J Cancer 1991; 47: 833-838.
71. Marks JR, Humphrey PA, Wu K, et al. Overexpression of p53 and HER-2/neu proteins as prognostic markers in early stage breast cancer. Ann Surg 1994; 219:332-341.
72. Kuerbitz SJ, Plunkett BS, Walsh WV, et al. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 1992; 89:7491-7495.
73. Yin Y, Tainsky MA, Bischoff FZ, et al. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 1992; 70:937-948.
74. Barnes DM, Bartkova J, Camplejohn RS, et al. Overexpression of the c-erb B-2 oncoprotein: why does this occur more frequently in ductal carcinoma in situ than in invasive mammary carcinoma and is this of prognostic significance? Eur J Cancer 1992; 28:644-648.
75. Liu E, Thor A, He M, et al. The HER2 (c-erb B-2) oncogene is frequently amplified in situ carcinomas of the breast. Oncogene 1992; 7:1027-1032.